ArticleAMIA ... Annual Symposium proceedings. AMIA Symposium2018
Identification of Rare Adverse Events with Year-varying Reporting Rates for FLU4 Vaccine in VAERS.
Article in AMIA ... Annual Symposium proceedings. AMIA Symposium, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 4 citations in OpenAlex.
- ZIBGLMM: Zero-inflated bivariate generalized linear mixed model for meta-analysis with double-zero-event studies.Research synthesis methods · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
In 2012, a new influenza vaccine - FLU4 was first licensed in the US. FLU4 is a quadrivalent flu vaccine, which can protect against four flu viruses. Compared to FLU and FLU3, FLU4 gives broader protection against the flu viruses. To our knowledge, few studies have focused on the FLU4 vaccine and its adverse events. Since safety signal detection is important in vaccination, it is necessary to launch such studies on FLU4. In this paper, we used the Vaccine Adverse Event Reporting System (VAERS), which is a national post-marketing vaccine safety surveillance program to identify rare adverse events with year-varying reporting rates for FLU4. The differences in the reporting rates over years are potential signals of vaccine safety issues caused by updates of FLU4 ingredients. We used a likelihood ratio test to simultaneously test the sparsity of events and the differences of event rates over years. We identified 4 adverse events that are rare and have significantly different reporting rates over years.
Indexed as
Identifiers
30815200PMC6371315W2941274749What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.